Search results
Results from the WOW.Com Content Network
A concussion, also known as a mild traumatic brain injury (mTBI), is a head injury that temporarily affects brain functioning. [8] Symptoms may include headache, dizziness, difficulty with thinking and concentration, sleep disturbances, mood changes, a brief period of memory loss, brief loss of consciousness; problems with balance; nausea; blurred vision; and mood changes.
Fast track is a designation by the United States Food and Drug Administration (FDA) of an investigational drug for expedited review to facilitate development of drugs that treat a serious or life-threatening condition and fill an unmet medical need. Fast track designation must be requested by the drug company.
Side effects of medications may affect people with mTBI more severely than they do others, and thus it is recommended that medications be avoided if possible; [51] there may be a benefit to avoiding narcotic medications. [52] In addition, some pain medications prescribed for headaches can cause rebound headaches when they are discontinued. [53]
Common diseases treated in neurointensive care units include strokes, ruptured aneurysms, brain and spinal cord injury from trauma, seizures (especially those that last for a long period of time- status epilepticus, and/or involve trauma to the patient, i.e., due to a stroke or a fall), swelling of the brain (Cerebral edema), infections of the ...
Commonly prescribed drugs are drugs that are frequently provided by doctors in a prescription to treat a certain disease. These drugs are often first-line treatment for the target diseases and are effective in tackling the symptoms. An example of the target disease is ischemic heart disease. Some examples of commonly prescribed drugs for this ...
On Tuesday, Oragenics Inc. (NYSE:OGEN) said it has completed a key study for its new concussion drug, ONP-002. What Happened: A recent study shows that the drug successfully targets areas inside ...
SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today provided a corporate update reflecting on the company’s progress throughout 2024, including key milestones in the development of ONP-002, its lead candidate for the treatment of concussions.
Closed-head injury is a type of traumatic brain injury in which the skull and dura mater remain intact. Closed-head injuries are the leading cause of death in children under 4 years old and the most common cause of physical disability and cognitive impairment in young people.